Skip to main content
Caplight Logo









SynDevRx

SynDevRx

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://syndevrx.com/

Last Round

Series C

Dec 22, 2025

Total Funding Raised

$31.33M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

SynDevRx is a clinical-stage biotechnology company that develops treatments for cancers sensitive to metabolic hormones.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug discoverymetabo-oncologyclinical trialsMetAP2 inhibitorcachexia treatmentsmall-molecule drugcancer metabolismbiotechevexomostatSDX-7320drug developmentmetabolic diseasetherapeutic candidateoncology research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SynDevRx Comparables

Compare SynDevRx with similar companies based on industry and business-model similarity.

SynDevRx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cureteq AG
80%
Kalohexis
79%
Actimed Therapeutics
78%

SynDevRx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CDec 22, 2025
GrantJan 9, 2025
VC RoundNov 4, 2024
GrantAug 31, 2022
Series BJan 25, 2022
Series B
Jan 9, 2020

Key People

Founding team and executive leadership

James Shanahan

Co-Founder, Chief Business Officer

Founding Team

Brad Carver

Co-founder, President, CEO and Chairman

Founding Team

David Neafus

CFO

Executive Team

SynDevRx Investors

Notable investors and investment history

SynDevRx investors
InvestorRounds
U.S. Department of WarGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors grew 190% MoM.

  • Dec 22, 2025

    Raised $6.4M in Series C funding.

SynDevRx Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SynDevRx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SynDevRx's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range11
Year Founded2007
Last FundingDec 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?